Tectonic Therapeutic
Tectonic Therapeutic
TECX
NASDAQ
26.35
USD
7.03%
About
AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.
The Company's development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 23.2K |
| Three Month Average Volume | 550.3K |
| High Low | |
| Fifty-Two Week High | 19.8 USD |
| Fifty-Two Week Low | 12.12 USD |
| Fifty-Two Week High Date | 06 Sep 2023 |
| Fifty-Two Week Low Date | 30 Jan 2024 |
| Price and Volume | |
| Current Price | 19.2 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 5.97% |
| Thirteen Week Relative Price Change | 1.01% |
| Twenty-Six Week Relative Price Change | 9.41% |
| Fifty-Two Week Relative Price Change | -16.00% |
| Year-to-Date Relative Price Change | -0.65% |
| Price Change | |
| One Day Price Change | 1.05% |
| Thirteen Week Price Change | 8.11% |
| Twenty-Six Week Price Change | 20.30% |
| Five Day Price Change | 5.49% |
| Fifty-Two Week Price Change | 5.26% |
| Year-to-Date Price Change | 17.65% |
| Month-to-Date Price Change | 7.14% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 25.46049 USD |
| Book Value Per Share (Most Recent Quarter) | 11.29112 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 25.46049 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 11.29112 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -16.79149 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 3.27329 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -18.52225 USD |
| Normalized (Last Fiscal Year) | -10.8888 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 3.29109 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -18.52225 USD |
| Including Extraordinary Items (Last Fiscal Year) | 3.27329 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -18.52225 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 26.34224 USD |
| Cash Per Share (Most Recent Quarter) | 12.56414 USD |
| Cash Flow Per Share (Last Fiscal Year) | 3.43942 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -17.76863 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -15.8072 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -16.19% |
| Tangible Book Value (5 Year) | -4.96% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -66.27% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -123.73% |
| EPS Change (Trailing Twelve Months) | -1,007.84% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -184,013,000 |
| Net Debt (Last Fiscal Year) | -98,020,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 5 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 4 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 0.00% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 14 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 16 |
| Current Ratio (Most Recent Quarter) | 7 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -63,198,000 |
| Free Cash Flow (Trailing Twelve Months) | -50,909,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -129 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 1 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 11.86% |
| Return on Assets (Trailing Twelve Months) | -35.55% |
| Return on Assets (5 Year) | -45.22% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 14.29% |
| Return on Equity (Trailing Twelve Months) | -40.40% |
| Return on Equity (5 Year) | -51.10% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 13.10% |
| Return on Investment (Trailing Twelve Months) | -40.16% |
| Return on Investment (5 Year) | -49.14% |